Insulin prices have fallen. Caps now limit out-of-pocket costs to $35 a month for many. Yet patients still face barriers. Delays. Denials. Endless forms. The system that was supposed to deliver relief after years of outrage has instead layered on new frustrations.
Steven E. Kahn and his co-authors at Diabetes Care put it plainly. A few brushes of a pen, some visible in budget requests and others hidden in administrative shifts, erode decades of progress. Their April 2026 editorial focused on threats to biomedical research funding at the National Institutes of Health. But the same critique applies to diabetes care delivery. Complacency has given way to concrete damage. Patients pay the price.
Consider the progress first. Drug makers responded to public pressure and government scrutiny. Eli Lilly, Novo Nordisk and Sanofi each capped monthly insulin costs at $35 for many patients. Minnesota reached settlements with all three companies, as reported by Reuters in January 2025. Novo Nordisk joined Lilly and Sanofi in agreeing patients would pay no more than that amount. The deals denied wrongdoing but pledged affordable access.
The Federal Trade Commission pursued pharmacy benefit managers aggressively. In February 2026 the agency settled with Cigna’s Express Scripts over allegations the company inflated insulin prices and steered patients to higher-cost options. The New York Times reported the deal requires fundamental changes in how the PBM interacts with employers, plans and pharmacies. The FTC claimed it could save Americans up to $7 billion in out-of-pocket costs over a decade. Similar proposed deals followed with CVS Caremark.
Yet the numbers tell a more complicated story. A January 2025 New York Times investigation revealed that some low-income patients at federally qualified health centers ended up paying more after manufacturers lowered list prices. The 340B program, designed to stretch scarce dollars, delivered smaller discounts once sticker prices dropped. Maricruz Salgado watched her quarterly diabetes medication costs rise despite the broader price reductions.
Paperwork as a New Gatekeeper
Prior authorization requirements have multiplied. Insurers demand documentation before covering insulin pumps, continuous glucose monitors or even certain insulin formulations. Providers spend hours on appeals. Patients wait weeks for approval. Some abandon treatment altogether.
Studies document the harm. One analysis in Primary Care Diabetes linked prior authorization for diabetes medications to worse clinical outcomes and widened health disparities. Patients forced to navigate these hurdles showed poorer glycemic control. Those from underserved communities suffered most. But the practice persists. Texas Medicaid updated its criteria in late 2025, adding layers for insulin pumps and supplies. Highmark imposed prior authorization on continuous glucose monitors for commercial plans starting in 2025.
Advocates point out the contradiction. Type 1 diabetes does not vanish. A patient stable on a regimen should not face annual reauthorization. Yet plans require it. One patient on X described fighting her Medicare Advantage plan for a GLP-1 medication, only to pay $45 monthly after approval. Another noted that documented need for insulin does not prevent yearly battles with insurers.
State legislatures have taken notice. In 2026 lawmakers in multiple states pushed reforms. Some bills require insurers to justify denials with peer-reviewed evidence. Others prohibit prior authorization for therapies with clear benefits, such as certain diabetes technologies. A Georgetown University Center for Health Insurance Reforms report from May 2026 highlighted growing frustration among both patients and physicians. Delays in care, the authors wrote, produce measurable damage.
The research community feels the squeeze too. Kahn’s editorial detailed an 89% drop in Notices of Funding Opportunities issued by NIH in the first 13 months of the current administration. Grant awards fell 66% in early fiscal 2026 compared with prior years. Diabetes-specific programs like the RISE study, DCCT/EDIC and TrialNet face uncertain futures. Without steady funding, innovation in better insulins, closed-loop systems and prevention strategies slows.
But the editorial’s real sting came at the American Diabetes Association’s 2026 scientific sessions in New Orleans. Researchers distributing copies of the piece were asked to stop. Security intervened. Some had their badges revoked. The episode, covered widely on social media and referenced in Washington Post reporting, underscored the tension. Criticism of policy, even when rooted in data, meets resistance.
And the data are clear. Fewer grants mean fewer trials. Slower progress on next-generation therapies. Higher long-term costs as preventable complications rise. One fragment stands out from the editorial: Enough is enough.
Pharmacy benefit managers defend their role. They negotiate rebates. They steer toward cost-effective options. Yet the FTC lawsuits alleged those same mechanisms sometimes inflated list prices to generate larger rebates, with patients left to shoulder higher copays before caps took effect. The settlements force transparency and new contracting models. Whether those changes reach patients remains to be seen.
Medicare’s $35 insulin cap, enacted through the Inflation Reduction Act, has endured. A Reuters fact check in January 2025 confirmed the cap survived executive actions aimed at other drug pricing rules. That protection matters for seniors. Commercial plans and Medicaid programs have followed with their own limits. Still, the uninsured, those in high-deductible plans and patients needing specific devices face gaps.
Sanofi expanded its $35 monthly cap to all insulin products effective 2026, according to Fierce Pharma. The move built on earlier price cuts for Lantus. Lilly and Novo Nordisk made similar commitments. These voluntary actions eased immediate pressure. They did not eliminate the administrative burden that follows.
Providers describe workflows consumed by paperwork. A recorded webinar from the Association of Diabetes Care and Education Specialists offers “prior authorization hacks” for insulin, GLP-1 agonists and diabetes technology. The very existence of such training reveals how routine the obstacle has become. Clinics hire staff whose sole job is to chase approvals. Time spent on forms is time taken from patient education and complication prevention.
The human cost accumulates quietly. A missed dose here. A delayed pump upgrade there. Elevated A1C levels. Increased emergency visits. Each prior authorization denial or delay carries downstream expenses that often exceed any short-term savings insurers claim.
Reform efforts continue. Bills in Congress and statehouses seek to limit how often prior authorization can be required for chronic therapies. Some propose automatic approval after a patient demonstrates stability on a medication. Others demand faster decisions, with 72-hour maximums for urgent requests. Progress is incremental. Industry pushback remains strong.
Kahn and his colleagues closed their piece with a call to action. Contact congressional representatives. Organizations that champion health must speak loudly. The same urgency applies to insulin access. Research without delivery mechanisms wastes potential. Price reductions without streamlined access leave patients in limbo.
So the brushes of the pen continue. Some sign price caps and funding bills. Others impose administrative rules that feel like obstacles rather than safeguards. Patients and physicians navigate both. The question now is whether lawmakers and regulators will recognize that effective policy must address both cost and friction. Otherwise the gains of recent years risk being dismantled one form at a time.
WebProNews is an iEntry Publication